Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 14, 2021JAMAOpen Access

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHui LuoSun Yat-sen UniversityJLJin LüSichuan Cancer HospitalYBYuxian BaiHarbin Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Luo et al. (2021) studied this question.

synapsesocial.com/papers/6a7cb403c9ba99be288ce857https://doi.org/10.1001/jama.2021.12836
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Phase II Trial of Paclitaxel and Cisplatin in Patients With Advanced Squamous-Cell Carcinoma of the Esophagus2008 · 87 citations
  2. 2Proportional hazards tests and diagnostics based on weighted residuals1994 · 5,798 citations
  3. 3Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer2018 · 544 citations
  4. 4Epidemiologic differences in esophageal cancer between Asian and Western populations2012 · 338 citations